Mapping of ebolavirus neutralization by monoclonal antibodies in the ZMapp cocktail using cryo-electron tomography and studies of cellular entry

Journal of Virology

Volumn 90, Issue 17, 2016, Pages 7618-7627

  Tran, Erin E H ^a   Nelson, Elizabeth A ^b   Bonagiri, Pranay ^b   Simmons, James A ^b   Shoemaker, Charles J ^c   Schmaljohn, Connie S ^c   Kobinger, Gary P ^d   Zeitlin, Larry ^e   Subramaniam, Sriram ^a   White, Judith M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e Mapp Biopharmaceutical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C13C6; MONOCLONAL ANTIBODY C2G4; MONOCLONAL ANTIBODY C4G7; NIEMANN PICK C1; PROTEIN NPC1; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; ZMAPP; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; NEUTRALIZING ANTIBODY; PROTEIN BINDING; VIROSOME; VIRUS ENVELOPE PROTEIN;

ANTIGEN BINDING; ARTICLE; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EBOLAVIRUS; ELECTRON TOMOGRAPHY; MEMBRANE BINDING; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; WEST AFRICAN; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; EBOLAVIRUS; ELECTRON MICROSCOPE TOMOGRAPHY; PROTEIN BINDING; VIRAL ENVELOPE PROTEINS; VIROSOMES; VIRUS INTERNALIZATION;

EID: 84981180343     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00406-16     Document Type: Article

References (42)

1. La Vega de M-A, Stein D, Kobinger GP. 2015. Ebolavirus evolution: past and present. PLoS Pathog 11:e1005221. http://dx.doi.org/10.1371/journal .ppat.1005221.
2. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53. http://dx.doi.org/10.1038/nature13777.
3. Davey RT. 2016. Prevail II: a randomized controlled trial of ZMapp in acute Ebola virus infection, abstr 77LB. Conf Retrovir Opportunistic Infect (CROI), Boston, MA, 22 to 25 February 2016.
4. Wilson J, Hevey M, Bakken R, Guest S, Bray M. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287:1664-1666. http://dx.doi.org/10.1126/science.287.5458.1664.
5. Qiu X, Alimonti JB, Melito PL, Fernando L, Ströher U, Jones SM. 2011. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 141:218-227. http://dx.doi.org/10.1016/j.clim .2011.08.008.
6. Qiu X, Fernando L, Melito PL, Audet J, Feldmann H, Kobinger G, Alimonti JB, Jones SM. 2012. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis 6:e1575. http://dx.doi.org/10.1371/journal.pntd.0001575.
7. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP. 2012. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4:138ra81. http://dx.doi.org/10.1126/scitranslmed.3003876.
8. Audet J, Wong G, Wang H, Lu G, Gao GF, Kobinger G, Qiu X. 2014. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep 4:6881. http://dx .doi.org/10.1038/srep06881.
9. Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO. 2014. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A 111:17182-17187. http://dx.doi.org/10.1073/pnas.1414164111.
10. Davidson E, Bryan C, Fong RH, Barnes T, Pfaff JM, Mabila M, Rucker JB, Doranz BJ. 2015. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J Virol 89:10982-10992. http://dx.doi.org/10.1128/JVI.01490-15.
11. Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM. 2013. Multiple cationic amphiphiles induce a Niemann-pick C phenotype and inhibit Ebola virus entry and infection. PLoS One 8:e56265. http://dx.doi.org/10.1371/journal.pone.0056265.
12. + endolysosomes is a rate-defining step. J Virol 89:2931-2943. http://dx.doi.org/10.1128/JVI.03398-14.
13. Kremer JR, Mastronarde DN, McIntosh JR. 1996. Computer visualization of three-dimensional image data using IMOD. J Struct Biol 116:71-76. http://dx.doi.org/10.1006/jsbi.1996.0013.
14. Tran EEH, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, Frank GA, Sapiro G, Milne JLS, Subramaniam S. 2012. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 8:e1002797. http://dx.doi.org/10.1371/journal.ppat.1002797.
15. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, la Cruz de MJ, Bess VJW, Nandwani R, Hoxie JA, Lifson JD, Milne JLS, Subramaniam S. 2010. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 6:e1001249. http://dx.doi.org/10.1371/journal.ppat .1001249.
16. Tran EEH, Simmons JA, Bartesaghi A, Shoemaker CJ, Nelson E, White JM, Subramaniam S. 2014. Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography. J Virol 88:10958-10962. http://dx.doi.org/10.1128/JVI.00870-14.
17. Kuybeda O, Frank GA, Bartesaghi A, Borgnia M, Subramaniam S, Sapiro G. 2013. A collaborative framework for 3D alignment and classification of heterogeneous subvolumes in cryo-electron tomography. J Struct Biol 181:116-127. http://dx.doi.org/10.1016/j.jsb.2012.10.010.
18. Ou W, Delisle J, Konduru K, Bradfute S, Radoshitzky SR, Retterer C, Kota K, Bavari S, Kuhn JH, Jahrling PB, Kaplan G, Wilson CA. 2011. Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins. J Virol Methods 174:99-109. http://dx .doi.org/10.1016/j.jviromet.2011.04.003.
19. Deffieu MS, Pfeffer SR. 2011. Niemann-Pick type C 1 function requires lumenal domain residues that mediate cholesterol-dependent NPC2 binding. Proc Natl Acad Sci U S A 108:18932-18936. http://dx.doi.org/10.1073/pnas.1110439108.
20. Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, Ruthel G, Pfeffer SR, Dye JM, Whelan SP, Brummelkamp TR, Chandran K. 2012. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J 31:1947-1960. http://dx.doi.org/10.1038/emboj.2012.53.
21. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. 2008. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454:177-182. http://dx.doi.org/10.1038/nature07082.
22. Dias JM, Kuehne AI, Abelson DM, Bale S, Wong AC, Halfmann P, Muhammad MA, Fusco ML, Zak SE, Kang E, Kawaoka Y, Chandran K, Dye JM, Saphire EO. 2011. A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol 18:1424-1427. http://dx.doi.org/10.1038/nsmb.2150.
23. Bournazos S, DiLillo DJ, Ravetch JV. 2015. The role of Fc-FcR interactions in IgG-mediated microbial neutralization. J Exp Med 212:1361-1369. http://dx.doi.org/10.1084/jem.20151267.
24. Olinger GG, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L. 2012. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 109:18030-18035. http://dx.doi.org/10.1073/pnas.1213709109.
25. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang C-C, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77:10557-10565. http://dx.doi.org/10.1128/JVI.77.19.10557-10565.2003.
26. Gire SK, Goba A, Andersen KG, Sealfon RSG, Park DJ, Kanneh L, Jalloh S, Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yozwiak NL, Winnicki S, Matranga CB, Malboeuf CM, Qu J, Gladden AD, Schaffner SF, Yang X, Jiang PP, Nekoui M, Colubri A, Coomber MR, Fonnie M, Moigboi A, Gbakie M, Kamara FK, Tucker V, Konuwa E, Saffa S, Sellu J, Jalloh AA, Kovoma A, Koninga J, Mustapha I, Kargbo K, Foday M, Yillah M, Kanneh F, Robert W, Massally JLB, Chapman SB, Bochicchio J, Murphy C, Nusbaum C, Young S, Birren BW, Grant DS, Scheiffelin JS, Lander ES, Happi C, Gevao SM, Gnirke A, Rambaut A, Garry RF, Khan SH, Sabeti PC. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369-1372. http://dx.doi.org/10.1126/science.1259657.
27. Hoenen T, Safronetz D, Groseth A, Wollenberg KR, Koita OA, Diarra B, Fall IS, Haidara FC, Diallo F, Sanogo M, Sarro YS, Kone A, Togo ACG, Traore A, Kodio M, Dosseh A, Rosenke K, de Wit E, Feldmann F, Ebihara H, Munster VJ, Zoon KC, Feldmann H, Sow S. 2015. Virology mutation rate and genotype variation of Ebola virus from Mali case sequences. Science 348:117-119. http://dx.doi.org/10.1126/science.aaa5646.
28. + endolysosomes. J Virol 90:605-610. http://dx.doi.org/10.1128/JVI.01828-15.
29. Spence JS, Krause TB, Mittler E, Jangra RK, Chandran K. 2016. Direct visualization of Ebola virus fusion triggering in the endocytic pathway. Chembiochem 7:e01857-15.
30. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. 2005. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645. http://dx.doi.org/10.1126/science.1110656.
31. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. 2006. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 80:4174-4178. http://dx.doi.org/10.1128/JVI.80.8.4174-4178.2006.
32. Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. 2011. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477:344-348. http://dx.doi.org/10.1038/nature10380.
33. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. 2011. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477:340-343. http://dx.doi.org/10.1038/nature10348.
34. Dube D, Brecher MB, Delos SE, Rose SC, Park EW, Schornberg KL, Kuhn JH, White JM. 2009. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol 83:2883-2891. http://dx.doi.org/10.1128/JVI.01956-08.
35. Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, Nabel GJ. 2010. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol 84:2972-2982. http://dx.doi.org/10.1128/JVI.02151-09.
36. Wang H, Shi Y, Song J, Qi J, Lu G, Yan J, Gao GF. 2016. Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. Cell 164:258-268. http://dx.doi.org/10.1016/j.cell.2015.12.044.
37. Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE, Chandran K, Saphire EO. 2016. Host-primed Ebola virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadly neutralizing antibodies. mBio 7:e02154-15. http://dx.doi.org/10.1128/mBio.02154-15.
38. Gregory SM, Harada E, Liang B, Delos SE, White JM, Tamm LK. 2011. Structure and function of the complete internal fusion loop from ebolavirus glycoprotein 2. Proc Natl Acad SciUSA 108:11211-11216. http://dx .doi.org/10.1073/pnas.1104760108.
39. White JM, Delos SE, Brecher M, Schornberg K. 2008. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol 43:189-219. http://dx.doi .org/10.1080/10409230802058320.
40. White JM, Schornberg KL. 2012. A new player in the puzzle of filovirus entry. Nat Rev Microbiol 10:317-322.
41. Khanna M, Sharma S, Kumar B, Rajput R. 2014. Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. Biomed Res Int 2014:546274.
42. Montero M, van Houten NE, Wang X, Scott JK. 2008. The membraneproximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 72:54-84. http://dx.doi.org/10.1128/MMBR.00020-07.